Condition

DLBCL clinical trials and research

• 21Clinical trials
• 10NIH research projects
• 33Countries

Newest DLBCL clinical trials

All recruiting trials (21)

• Rocbrutinib plus R-GemOx for relapsed/refractory DLBCL

  This early-stage study tests whether combining Rocbrutinib with R-GemOx is safe and shows promise in people with relapsed or refractory non-GCB DLBCL.

  Recruiting at 2 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Guangzhou, Guangdong and 1 other locations · NCT07570017

• Real-world data and samples from frail or multiply treated large B‑cell lymphoma patients

  This project collects health records and blood and tissue samples from older, frail, or multiply treated people with diffuse large B‑cell lymphoma to see which treatments they receive and how they fare.

  Recruiting The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, Merseyside · NCT07335120

• BAFF-R CAR-T therapy for relapsed or refractory BAFF-R–positive B-cell lymphoma

  This trial will test whether a BAFF‑R–targeted CAR‑T cell therapy is safe and can help adults with relapsed or refractory BAFF‑R–positive B‑cell lymphomas (such as DLBCL, CLL, FL, MCL, or WM).

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07259070

• Anti-EBV autologous TCR-T cell injection for relapsed or refractory EBV-positive lymphoma

  This trial will test whether injections of a patient's own anti-EBV TCR-T cells are safe and help adults (18–70) with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01.

  Recruiting Early Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07162012

• Predicting response to first-line DLBCL treatment using ctDNA and PET/CT

  This project will test whether combining a blood ctDNA test with PET/CT scans after two treatment cycles can predict treatment response in people newly diagnosed with DLBCL who are starting standard first-line therapy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07070648

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

• Evaluating tucidinostat for treating newly diagnosed DLBCL patients

  This study is testing if a new drug called tucidinostat can help newly diagnosed patients with diffuse large B-cell lymphoma feel better and stay safe, comparing results between those who can and can't handle standard chemotherapy.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06779435

• Treatment for elderly patients with DLBCL who can't tolerate chemotherapy

  This study is testing a new combination treatment for older patients with diffuse large B-cell lymphoma who can't handle traditional chemotherapy to see if it can help them.

  Recruiting Phase 2 First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT06758037

• New treatment for previously untreated diffuse large B-cell lymphoma

  This study tests a new combination treatment for people with newly diagnosed double-expression lymphoma to see if it works better based on their genetic makeup.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06701357

• Using Trilaciclib with Chemotherapy for Patients with Diffuse Large B-Cell Lymphoma

  This study is testing if adding Trilaciclib to chemotherapy can help people with diffuse large B-cell lymphoma avoid serious side effects like low white blood cell counts.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06569485

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Combining Tafasitamab and Lenalidomide with Gemcitabine and Oxaliplatin for treating relapsed DLBCL

  This study is testing a new combination of medications for people with relapsed DLBCL to see if it works better than the standard treatment.

  Recruiting at 3 sites Phase 3 Beijing InnoCare Pharma Tech Co., Ltd. · Beijing and 19 other locations · NCT06521255

• Combining Tafasitamab and Lenalidomide for treating relapsed DLBCL

  This study is testing if combining Tafasitamab and Lenalidomide can help people with relapsed or hard-to-treat Diffuse Large B-Cell Lymphoma feel better.

  Recruiting Phase 2 Beijing InnoCare Pharma Tech Co., Ltd. · Hangzhou, Zhejiang · NCT05552937

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Evaluating RNK05047 for advanced solid tumors and DLBCL

  This study is testing a new drug called RNK05047 to see if it can safely help people with advanced solid tumors and diffuse large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Ranok Therapuetics Co. Ltd. · Atlanta, Georgia and 4 other locations · NCT05487170

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using zilovertamab vedotin

  This study is testing a new treatment called zilovertamab vedotin for adults with relapsed or refractory diffuse large B-cell lymphoma to see if it works better than standard care.

  Recruiting at 43 sites Phase 2/3 Merck Sharp & Dohme LLC · Glendale, Arizona and 134 other locations · NCT05139017

• Combining Lenalidomide with R-DA-EPOCH for Untreated DLBCL with MYC Rearrangement

  This study is testing if adding lenalidomide to a specific chemotherapy treatment can help people with untreated diffuse large B-cell lymphoma that has a MYC gene rearrangement.

  Recruiting Phase 1/2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT04432714

• Comparing two treatments for elderly patients with diffuse large B-cell lymphoma

  This study is testing whether a new treatment for elderly patients with diffuse large B-cell lymphoma works better than the standard treatment.

  Recruiting at 52 sites Phase 3 Nordic Lymphoma Group · Albury and 68 other locations · NCT04332822

• Combining acalabrutinib with standard chemotherapy for untreated aggressive B-cell lymphoma

  This study is testing if adding a new drug called acalabrutinib to standard chemotherapy can help people with untreated aggressive B-cell lymphoma get better results.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04002947

• Using PET scans and blood tests to improve treatment for early stage lymphoma

  This study is testing if measuring tumor DNA in the blood can help doctors adjust treatment for patients with early stage lymphoma to improve their chances of success.

  Recruiting Phase 2 University of Rochester · Rochester, New York · NCT03758989

• Treatment for CD30 Positive Diffuse Large B-cell Lymphoma Patients Who Didn't Respond to Initial Chemotherapy

  This study is testing a new treatment combining brentuximab vedotin and chemotherapy for patients with CD30 positive diffuse large B-cell lymphoma who didn't respond to their first chemotherapy, to see if it can improve their chances of recovery.

  Recruiting Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Rotterdam · NCT03356054

NIH-funded research (10)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Translating Genomics to Practice to Overcome Disparities in DLBCL

  A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11401446

• Enhancing CART-T therapy for B-cell lymphoma with longer-lasting IL-7/IL-15/IL-21 support

  This grant tests a new treatment approach that combines CAR-T cells for large B-cell lymphoma with a long-acting growth factor cocktail to help the CAR-T cells expand and persist.

  NIH research Washington University · Saint Louis, United States · NIH-11365474

• How Epstein-Barr virus contributes to aggressive B‑cell lymphoma (DLBCL)

  This work looks at how Epstein‑Barr virus affects certain types of diffuse large B‑cell lymphoma (DLBCL) to find new treatment targets for people with DLBCL, including those living with HIV.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11322132

• Using lymphoma's own faulty proteins to trigger self‑destruction in diffuse large B‑cell lymphoma

  New small molecules aim to bring lymphoma's abnormal proteins to the right DNA switches so diffuse large B‑cell lymphoma cells turn on self‑destruct genes.

  NIH research Stanford University · Stanford, United States · NIH-11237062

• Analyzing genetic mutations in cancer to improve treatment

  This study is looking at the genetic changes that cause cancer to help doctors find better, personalized treatments for cancer patients like you.

  NIH research Broad Institute, INC. · Cambridge, United States · NIH-11191176

• Targeting MALT1 in African American adults with diffuse large B‑cell lymphoma

  This project is developing MALT1‑blocking drugs to help African American adults with aggressive or treatment‑resistant diffuse large B‑cell lymphoma.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11187680

• Targeting EBV-related lymphoma with a new medicine

  This project is developing a new medicine to help people with a type of lymphoma caused by the Epstein-Barr virus.

  NIH research Wistar Institute · Philadelphia, United States · NIH-11125780

• Using cancer drivers to trigger cell death in lymphoma

  This study is exploring a new way to help people with Diffuse Large B-Cell Lymphoma by using special molecules that can help cancer cells turn on their own self-destruct buttons, making existing treatments work better and offering a fresh option for patients.

  NIH research Stanford University · Stanford, United States · NIH-10982470

• Targeted therapy for relapsed B-cell leukemia and lymphoma using CAR T-cells

  This study is testing a new treatment for adults with tough-to-treat B-cell leukemia and lymphoma, using special CAR T-cells along with a unique method to help make the treatment safer and more effective.

  NIH research Actinium Pharmaceuticals, INC. · New York, UNITED STATES · NIH-10892773

• New treatment for a type of lymphoma caused by Epstein-Barr Virus

  This study is looking at a new treatment called VK-2019 for people with a type of cancer called EBV-positive Diffuse Large B-Cell Lymphoma, and it aims to see how safe and effective this treatment is in lowering the virus levels in the blood.

  NIH research Wistar Institute · Philadelphia, United States · NIH-10884413

Related topics

Quick answers

How many DLBCL clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in China (13 trials), United States (7 trials), Italy (3 trials), United Kingdom (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1/2: 4, Phase 1: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →